Reisa A Sperling

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7916145/publications.pdf

Version: 2024-02-01

		4653	1713
458	51,073	85	213
papers	citations	h-index	g-index

594	594	594	35282
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	NIAâ€AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.4	5,861
2	Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 280-292.	0.4	5,550
3	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. New England Journal of Medicine, 2012, 367, 795-804.	13.9	3,005
4	Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease. Journal of Neuroscience, 2009, 29, 1860-1873.	1.7	2,576
5	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.4	1,863
6	Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. New England Journal of Medicine, 2014, 370, 322-333.	13.9	1,613
7	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.4	1,318
8	Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology, The, 2016, 15, 455-532.	4.9	1,242
9	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547.	1.5	1,216
10	Alzheimer's disease. Nature Reviews Disease Primers, 2015, 1, 15056.	18.1	1,210
11	Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia. Neuron, 2009, 63, 178-188.	3.8	899
12	Tau positron emission tomographic imaging in aging and early <scp>A</scp>lzheimer disease. Annals of Neurology, 2016, 79, 110-119.	2.8	778
13	The A4 Study: Stopping AD Before Symptoms Begin?. Science Translational Medicine, 2014, 6, 228fs13.	5.8	588
14	The Evolution of Preclinical Alzheimerâ€™s Disease: Implications for Prevention Trials. Neuron, 2014, 84, 608-622.	3.8	568
15	The Preclinical Alzheimer Cognitive Composite. JAMA Neurology, 2014, 71, 961.	4.5	548
16	Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimerâ€™s Association Research Roundtable Workgroup. , 2011, 7, 367-385.		531
17	Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden. Journal of Neuroscience, 2009, 29, 12686-12694.	1.7	530
18	Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease. JAMA Neurology, 2019, 76, 915.	4.5	512

#	Article	IF	Citations
19	Functional Alterations in Memory Networks in Early Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2010, 12, 27-43.	1.8	497
20	Testing the Right Target and Right Drug at the Right Stage. Science Translational Medicine, 2011, 3, 111cm33.	5.8	459
21	Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurology, The, 2012, 11, 1048-1056.	4.9	450
22	Cerebral amyloid angiopathy and Alzheimer disease â€" one peptide, two pathways. Nature Reviews Neurology, 2020, 16, 30-42.	4.9	407
23	Symptom onset in autosomal dominant Alzheimer disease. Neurology, 2014, 83, 253-260.	1.5	391
24	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurology, The, 2012, 11, 241-249.	4.9	390
25	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Annals of Neurology, 2016, 79, 929-939.	2.8	381
26	Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia, 2012, 50, 2880-2886.	0.7	379
27	Implementation of subjective cognitive decline criteria in research studies. Alzheimer's and Dementia, 2017, 13, 296-311.	0.4	375
28	Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2181-2186.	3.3	344
29	Resistance to autosomal dominant Alzheimerâ€™s disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 2019, 25, 1680-1683.	15.2	328
30	Putting names to faces:. NeuroImage, 2003, 20, 1400-1410.	2.1	319
31	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	1.2	317
32	On the path to 2025: understanding the Alzheimerâ€™s disease continuum. Alzheimer's Research and Therapy, 2017, 9, 60.	3.0	316
33	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA - Journal of the American Medical Association, 2017, 317, 2305.	3.8	311
34	Amyloidâ€Î²2 associated cortical thinning in clinically normal elderly. Annals of Neurology, 2011, 69, 1032-1042.	2.8	306
35	Research priorities to reduce the global burden of dementia by 2025. Lancet Neurology, The, 2016, 15, 1285-1294.	4.9	284
36	Synergistic Effect of Î²-Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals. JAMA Neurology, 2014, 71, 1379.	4.5	273

#	Article	IF	Citations
37	Loneliness, depression and cognitive function in older U.S. adults. International Journal of Geriatric Psychiatry, 2017, 32, 564-573.	1.3	269
38	Amyloid and APOE Îµ4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology, 2014, 82, 1760-1767.	1.5	246
39	Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals. Journal of Neuroscience, 2017, 37, 4323-4331.	1.7	237
40	The parahippocampal gyrus links the defaultâ€mode cortical network with the medial temporal lobe memory system. Human Brain Mapping, 2014, 35, 1061-1073.	1.9	236
41	Preclinical Alzheimer diseaseâ€"the challenges ahead. Nature Reviews Neurology, 2013, 9, 54-58.	4.9	232
42	Suspected non-Alzheimer disease pathophysiology â€" concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	4.9	230
43	Different partial volume correction methods lead to different conclusions: An 18F-FDG-PET study of aging. NeuroImage, 2016, 132, 334-343.	2.1	216
44	Functional MRI Studies of Associative Encoding in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease. Annals of the New York Academy of Sciences, 2007, 1097, 146-155.	1.8	210
45	Amyloid-Î² deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain, 2015, 138, 1023-1035.	3.7	207
46	Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurology, 2019, 76, 542.	4.5	201
47	Functional MRI detection of pharmacologically induced memory impairment. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 455-460.	3.3	198
48	Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nature Neuroscience, 2018, 21, 424-431.	7.1	198
49	Partial volume correction in quantitative amyloid imaging. NeuroImage, 2015, 107, 55-64.	2.1	188
50	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurology, 2020, 77, 735.	4.5	182
51	Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. American Journal of Psychiatry, 2018, 175, 530-537.	4.0	175
52	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology, 2013, 81, 736-744.	1.5	174
53	The impact of amyloidâ€beta and tau on prospective cognitive decline in older individuals. Annals of Neurology, 2019, 85, 181-193.	2.8	171
54	Sex, amyloid, and APOE Îµ4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three wellâ€characterized cohorts. Alzheimer's and Dementia, 2018, 14, 1193-1203.	0.4	169

#	Article	IF	Citations
55	Subjective Cognitive Concerns and Neuropsychiatric Predictors of ProgressionÂto the Early Clinical Stages ofÂAlzheimer Disease. American Journal of Geriatric Psychiatry, 2014, 22, 1642-1651.	0.6	167
56	Interactive Associations of Vascular Risk and Î²-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals. JAMA Neurology, 2018, 75, 1124.	4.5	165
57	Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. JAMA Psychiatry, 2016, 73, 1230.	6.0	164
58	Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 668-677.	1.8	160
59	Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology, 2016, 87, 481-488.	1.5	159
60	Large-Scale Functional Brain Network Abnormalities in Alzheimerâ€™s Disease: Insights from Functional Neuroimaging. Behavioural Neurology, 2009, 21, 63-75.	1.1	156
61	What Happens with the Circuit in Alzheimer's Disease in Mice and Humans?. Annual Review of Neuroscience, 2018, 41, 277-297.	5.0	154
62	In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. Journal of Neuroscience, 2016, 36, 7364-7374.	1.7	153
63	Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimerâ€™s Disease. New England Journal of Medicine, 2019, 380, 1483-1485.	13.9	149
64	Promising developments in neuropsychological approaches for the detection of preclinical Alzheimerâ€™s disease: a selective review. Alzheimer's Research and Therapy, 2013, 5, 58.	3.0	146
65	Multiple Brain Markers are Linked to Age-Related Variation in Cognition. Cerebral Cortex, 2016, 26, 1388-1400.	1.6	146
66	Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia. JAMA Neurology, 2015, 72, 446.	4.5	142
67	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid Î². Alzheimer's and Dementia, 2017, 13, 1004-1012.	0.4	139
68	Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2018, 75, 548.	4.5	137
69	Amyloid-Î² ¹¹ C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology, 2015, 85, 692-700.	1.5	136
70	Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nature Medicine, 2018, 24, 1910-1918.	15.2	135
71	The potential of functional MRI as a biomarker in early Alzheimer's disease. Neurobiology of Aging, 2011, 32, S37-S43.	1.5	134
72	CD33 modulates TREM2: convergence of Alzheimer loci. Nature Neuroscience, 2015, 18, 1556-1558.	7.1	134

#	Article	IF	Citations
73	Subjective cognitive concerns, amyloid-Î², and neurodegeneration in clinically normal elderly. Neurology, 2015, 85, 56-62.	1.5	127
74	Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology, 2015, 84, 2153-2160.	1.5	120
75	Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global Î²-Amyloid Burden. JAMA Neurology, 2017, 74, 1455.	4.5	119
76	Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiology of Aging, 2013, 34, 822-831.	1.5	118
77	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1111.	4.5	112
78	The cortical origin and initial spread of medial temporal tauopathy in Alzheimerâ€™s disease assessed with positron emission tomography. Science Translational Medicine, 2021, 13, .	5.8	111
79	Fluorodeoxyglucose metabolism associated with tauâ€amyloid interaction predicts memory decline. Annals of Neurology, 2017, 81, 583-596.	2.8	110
80	Harvard Aging Brain Study: Dataset and accessibility. NeuroImage, 2017, 144, 255-258.	2.1	107
81	In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimerâ€™s disease pathology and cognitive decline. Science Translational Medicine, 2021, 13, eabj2511.	5.8	107
82	Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimer's Research and Therapy, 2015, 7, 26.	3.0	106
83	Functional network integrity presages cognitive decline in preclinical Alzheimer disease. Neurology, 2017, 89, 29-37.	1.5	106
84	Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE Îµ4 haplotype status: a community-based cohort study. Lancet Neurology, The, 2018, 17, 773-781.	4.9	101
85	Dissecting the genetic relationship between cardiovascular risk factors and Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 137, 209-226.	3.9	100
86	Associations of Physical Activity and Î²-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurology, 2019, 76, 1203.	4.5	97
87	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
88	Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study. Lancet Neurology, The, 2016, 15, 811-819.	4.9	96
89	Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2015, 72, 912.	4.5	94
90	PET staging of amyloidosis using striatum. Alzheimer's and Dementia, 2018, 14, 1281-1292.	0.4	93

#	Article	IF	Citations
91	Tau and amyloid Î² proteins distinctively associate to functional network changes in the aging brain. Alzheimer's and Dementia, 2017, 13, 1261-1269.	0.4	90
92	Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional data. PLoS Medicine, 2017, 14, e1002287.	3.9	88
93	Depressive Symptoms and Biomarkers of Alzheimerâ€™s Disease in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2015, 46, 63-73.	1.2	87
94	Regional Cortical Thinning Predicts Worsening Apathy and Hallucinations Across the Alzheimer Disease Spectrum. American Journal of Geriatric Psychiatry, 2014, 22, 1168-1179.	0.6	86
95	Relationships between default-mode network connectivity, medial temporal lobe structure, and age-related memory deficits. Neurobiology of Aging, 2015, 36, 265-272.	1.5	86
96	Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology, 2016, 87, 920-926.	1.5	86
97	CAPâ€”advancing the evaluation of preclinical Alzheimer disease treatments. Nature Reviews Neurology, 2016, 12, 56-61.	4.9	80
98	Alzheimerâ€™s Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. Journal of Alzheimer's Disease, 2017, 60, 1451-1459.	1.2	80
99	Preferential degradation of cognitive networks differentiates Alzheimerâ€™s disease from ageing. Brain, 2018, 141, 1486-1500.	3.7	79
100	Vascular Risk and Î²â€Amyloid Are Synergistically Associated with Cortical Tau. Annals of Neurology, 2019, 85, 272-279.	2.8	75
101	Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity. Journal of Neuroscience, 2019, 39, 548-556.	1.7	75
102	The association between tau PET and retrospective cortical thinning in clinically normal elderly. NeuroImage, 2017, 157, 612-622.	2.1	74
103	Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. JAMA Network Open, 2019, 2, e198964.	2.8	72
104	Dissociable influences of APOE Îµ4 and polygenic risk of AD dementia on amyloid and cognition. Neurology, 2018, 90, e1605-e1612.	1.5	71
105	Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. Journal of Alzheimer's Disease, 2017, 59, 975-985.	1.2	70
106	Functional Connectivity in Multiple Cortical Networks Is Associated with Performance Across Cognitive Domains in Older Adults. Brain Connectivity, 2015, 5, 505-516.	0.8	69
107	Memory self-awareness in the preclinical and prodromal stages of Alzheimerâ€™s disease. Neuropsychologia, 2017, 99, 343-349.	0.7	67
108	18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. Journal of Alzheimer's Disease, 2018, 62, 1691-1702.	1.2	67

#	Article	IF	Citations
109	Amyloid Deposition Is Linked to Aberrant Entorhinal Activity among Cognitively Normal Older Adults. Journal of Neuroscience, 2014, 34, 5200-5210.	1.7	65
110	The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 47, 421-432.	1.2	65
111	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nature Reviews Neurology, 2021, 17, 703-714.	4.9	65
112	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
113	Polygenic hazard score, amyloid deposition and Alzheimerâ€™s neurodegeneration. Brain, 2019, 142, 460-470.	3.7	63
114	Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging. NeuroImage: Clinical, 2017, 15, 408-414.	1.4	61
115	Cardiorespiratory fitness is differentially associated with cortical thickness in young and older adults. NeuroImage, 2017, 146, 1084-1092.	2.1	61
116	Biomarker validation of a decline in semantic processing in preclinical Alzheimerâ€™s disease.. Neuropsychology, 2016, 30, 624-630.	1.0	60
117	Subjective cognitive concerns, episodic memory, and the APOE Îµ4 allele. Alzheimer's and Dementia, 2014, 10, 752.	0.4	57
118	Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimerâ€™s disease. Neuropsychologia, 2015, 73, 169-175.	0.7	57
119	Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease. Neurobiology of Aging, 2016, 42, 177-188.	1.5	57
120	Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease. JAMA Neurology, 2021, 78, 293.	4.5	57
121	Social Engagement and Amyloid-Î²-Related Cognitive Decline in Cognitively Normal Older Adults. American Journal of Geriatric Psychiatry, 2019, 27, 1247-1256.	0.6	56
122	Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimer's and Dementia, 2020, 16, 552-560.	0.4	55
123	Cognitive resilience in clinical and preclinical Alzheimerâ€™s disease: the Association of Amyloid and Tau Burden on cognitive performance. Brain Imaging and Behavior, 2017, 11, 383-390.	1.1	54
124	Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiology of Aging, 2019, 78, 178-185.	1.5	54
125	Stress, resilience, and coping strategies in a sample of community-dwelling older adults during COVID-19. Journal of Psychiatric Research, 2021, 138, 176-185.	1.5	53
126	Estimating Total Cerebral Microinfarct Burden From Diffusion-Weighted Imaging. Stroke, 2015, 46, 2129-2135.	1.0	52

#	Article	IF	Citations
127	Heterogeneity in Suspected Nonâ€“Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. JAMA Neurology, 2016, 73, 1185.	4.5	52
128	Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study. Neurology, 2021, 96, e1491-e1500.	1.5	52
129	Regional Cortical Thinning and Cerebrospinal Biomarkers Predict Worsening Daily Functioning Across the Alzheimer's Disease Spectrum. Journal of Alzheimer's Disease, 2014, 41, 719-728.	1.2	51
130	Amyloidâ€ssociated increases in longitudinal report of subjective cognitive complaints. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 444-449.	1.8	51
131	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.4	51
132	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimerâ€™s disease. PLoS ONE, 2018, 13, e0195838.	1.1	51
133	Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden. Neurology, 2017, 88, 1759-1767.	1.5	50
134	Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimerâ€™s Disease Biomarkers. Journal of Alzheimer's Disease, 2016, 50, 249-260.	1.2	50
135	Dedifferentiation of caudate functional connectivity and striatal dopamine transporter density predict memory change in normal aging. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10160-10165.	3.3	49
136	Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. JAMA Neurology, 2020, 77, 1504.	4.5	48
137	Template based rotation: A method for functional connectivity analysis with a priori templates. NeuroImage, 2014, 102, 620-636.	2.1	47
138	Cardiorespiratory fitness is associated with white matter integrity in aging. Annals of Clinical and Translational Neurology, 2015, 2, 688-698.	1.7	47
139	Global White Matter Diffusion Characteristics Predict Longitudinal Cognitive Change Independently of Amyloid Status in Clinically Normal Older Adults. Cerebral Cortex, 2019, 29, 1251-1262.	1.6	47
140	Task-Induced Brain Activity Patterns in Type 2 Diabetes: A Potential Biomarker for Cognitive Decline. Diabetes, 2014, 63, 3112-3119.	0.3	46
141	Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology, 2017, 88, 1431-1438.	1.5	46
142	Regional tau pathology and loneliness in cognitively normal older adults. Translational Psychiatry, 2018, 8, 282.	2.4	46
143	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimerâ€™s Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	1.1	45
144	Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. Neurology, 2021, 96, e619-e631.	1.5	45

#	Article	IF	Citations
145	Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 46, 727-735.	1.2	44
146	Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly. Journal of Alzheimer's Disease, 2016, 53, 1097-1105.	1.2	44
147	Subjective cognitive concerns are associated with objective memory performance in Caucasian but not African-American persons. Age and Ageing, 2017, 46, 988-993.	0.7	44
148	Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. Nature Communications, 2020, 11, 6024.	5.8	43
149	The A4 study: Î²â€amyloid and cognition in 4432 cognitively unimpaired adults. Annals of Clinical and Translational Neurology, 2020, 7, 776-785.	1.7	43
150	Predicting Reduction of Cerebrospinal Fluid Î²-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurology, 2015, 72, 554.	4.5	42
151	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. Alzheimer's and Dementia, 2016, 12, 614-622.	0.4	42
152	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 1225.	1.6	42
153	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: AÂserial magnetic resonance imaging study. Alzheimer's and Dementia, 2018, 14, 43-53.	0.4	42
154	The Ups and Downs of the Posteromedial Cortex: Age- and Amyloid-Related Functional Alterations of the Encoding/Retrieval Flip in Cognitively Normal Older Adults. Cerebral Cortex, 2013, 23, 1317-1328.	1.6	41
155	Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. JAMA Neurology, 2020, 77, 1288.	4.5	41
156	Plasma ILâ€12/IFNâ€Î³ axis predicts cognitive trajectories in cognitively unimpaired older adults. Alzheimer's and Dementia, 2022, 18, 645-653.	0.4	39
157	THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS. journal of prevention of Alzheimer's disease, The, 2016, 3, 1-5.	1.5	39
158	Regional Fluorodeoxyglucose Metabolism and Instrumental Activities of Daily Living across the Alzheimer's Disease Spectrum. Journal of Alzheimer's Disease, 2014, 42, 291-300.	1.2	38
159	Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults. Neurology, 2021, 96, e1844-e1854.	1.5	38
160	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. NeuroImage, 2021, 231, 117845.	2.1	38
161	Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease. American Journal of Geriatric Psychiatry, 2017, 25, 683-693.	0.6	37
162	Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology, 2015, 85, 48-55.	1.5	36

#	Article	IF	Citations
163	Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. Annals of Neurology, 2016, 80, 846-857.	2.8	36
164	Neuroimaging markers associated with maintenance of optimal memory performance in late-life. Neuropsychologia, 2017, 100, 164-170.	0.7	35
165	Biomarkers of Alzheimer Disease. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 325-338.	0.4	34
166	Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimerâ€™s disease: findings from the Colombia-Boston (COLBOS) biomarker study. Alzheimer's Research and Therapy, 2021, 13, 27.	3.0	34
167	Variant-dependent heterogeneity in amyloid Î² burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	4.9	34
168	Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimerâ€™s Disease Dementia. Journal of Alzheimer's Disease, 2019, 67, 757-768.	1.2	32
169	Lower novelty-related locus coeruleus function is associated with AÎ²-related cognitive decline in clinically healthy individuals. Nature Communications, 2022, 13, 1571.	5.8	32
170	Peripheral and central effects of Î³-secretase inhibition by semagacestat in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 36.	3.0	31
171	Trans -pQTL study identifies immune crosstalk between Parkinson and Alzheimer loci. Neurology: Genetics, 2016, 2, e90.	0.9	31
172	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiology of Disease, 2020, 142, 104960.	2.1	31
173	Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults. NeuroImage, 2020, 220, 116991.	2.1	31
174	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimerâ€™s Disease. Journal of the International Neuropsychological Society, 2021, 27, 426-438.	1.2	30
175	Genetics of Gene Expression in the Aging Human Brain Reveal TDP-43 Proteinopathy Pathophysiology. Neuron, 2020, 107, 496-508.e6.	3.8	29
176	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. JAMA Neurology, 2022, 79, 592.	4.5	29
177	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology, 2018, 90, e877-e886.	1.5	28
178	Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Molecular Psychiatry, 2020, 25, 2599-2607.	4.1	28
179	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology, 2015, 85, 790-798.	1.5	27
180	Seizures as an early symptom of autosomal dominant Alzheimer's disease. Neurobiology of Aging, 2019, 76, 18-23.	1.5	27

#	Article	IF	Citations
181	Associations of Widowhood and Î²-Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults. JAMA Network Open, 2020, 3, e200121.	2.8	27
182	Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults. Neurobiology of Aging, 2020, 93, 124-130.	1.5	27
183	Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimer's and Dementia, 2016, 12, 631-632.	0.4	26
184	Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 14.	3.0	26
185	Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 17.	3.0	26
186	Amyloid-Î² and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2113641119.	3.3	26
187	Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity. Human Brain Mapping, 2016, 37, 621-631.	1.9	24
188	Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2022, 14, 54.	3.0	24
189	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. Alzheimer's and Dementia, 2016, 12, 510-515.	0.4	23
190	Decreased hippocampal metabolism in highâ€amyloid mild cognitiveÂimpairment. Alzheimer's and Dementia, 2016, 12, 1288-1296.	0.4	23
191	Subjective memory complaints in preclinical autosomal dominant Alzheimer disease. Neurology, 2017, 89, 1464-1470.	1.5	23
192	The Impact of Awareness of and Concern About Memory Performance on the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease Dementia. American Journal of Geriatric Psychiatry, 2018, 26, 896-904.	0.6	23
193	â€œAlzheimer's diseaseâ€•is neither â€œAlzheimer's clinical syndromeâ€•nor â€œdementiaâ€• Alzheimer's and Dementia, 2019, 15, 153-157.	0.4	23
194	Resting-state functional connectivity and amyloid burden influence longitudinal cortical thinning in the default mode network in preclinical Alzheimerâ€™s disease. NeuroImage: Clinical, 2020, 28, 102407.	1.4	23
195	Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies. Journal of Alzheimer's Disease, 2018, 66, 1409-1424.	1.2	22
196	Amyloid imaging of dutchâ€type hereditary cerebral amyloid angiopathy carriers. Annals of Neurology, 2019, 86, 616-625.	2.8	22
197	Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 99.	3.0	22
198	The impact of COVID-19 on the well-being and cognition of older adults living in the United States and Latin America. EClinicalMedicine, 2021, 35, 100848.	3.2	22

#	Article	IF	Citations
199	Dementia: new criteria but no new treatments. Lancet Neurology, The, 2012, 11, 4-5.	4.9	21
200	Racial and socioeconomic status differences in stress, posttraumatic growth, and mental health in an older adult cohort during the COVID-19 pandemic. EClinicalMedicine, 2022, 45, 101343.	3.2	21
201	Association of Emerging Î²-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults. Neurology, 2022, 98, .	1.5	20
202	Flexible modulation of network connectivity related to cognition in Alzheimer's disease. NeuroImage, 2014, 100, 544-557.	2.1	18
203	Longitudinal degradation of the default/salience network axis in symptomatic individuals with elevated amyloid burden.. NeuroImage: Clinical, 2020, 26, 102052.	1.4	18
204	Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. Journal of Alzheimer's Disease, 2020, 75, 1437-1446.	1.2	18
205	Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. Neurology, 2021, 96, .	1.5	18
206	Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-Î² and Tau Pathology in Middle-Aged Adults: The Framingham Study. Journal of Alzheimer's Disease, 2022, 86, 1371-1383.	1.2	18
207	The influence of demographic factors on subjective cognitive concerns and beta-amyloid. International Psychogeriatrics, 2017, 29, 645-652.	0.6	17
208	Synergism between fornix microstructure and beta amyloid accelerates memory decline in clinically normal older adults. Neurobiology of Aging, 2019, 81, 38-46.	1.5	17
209	Word retrieval across the biomarker-confirmed Alzheimer's disease syndromic spectrum. Neuropsychologia, 2020, 140, 107391.	0.7	17
210	Association of cortical microstructure with amyloid-Î² and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. Molecular Psychiatry, 2021, 26, 7813-7822.	4.1	17
211	Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers. NeuroImage, 2019, 186, 446-454.	2.1	16
212	Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimerâ€™s Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. Journal of Alzheimer's Disease, 2018, 64, 689-707.	1.2	15
213	Age-Related Increases in Tip-of-the-tongue are Distinct from Decreases in Remembering Names: A Functional MRI Study. Cerebral Cortex, 2017, 27, 4339-4349.	1.6	14
214	AHEAD 3â€45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimerâ€™s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial). Alzheimer's and Dementia, 2020, 16, e044511.	0.4	14
215	Decline in cognitively complex everyday activities accelerates along the Alzheimerâ€™s disease continuum. Alzheimer's Research and Therapy, 2020, 12, 138.	3.0	14
216	Feasibility study for detection of retinal amyloid in clinical trials: The Antiâ€Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12199.	1.2	14

#	Article	IF	Citations
217	The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease. journal of prevention of Alzheimer's disease, The, 2015, 2, 242-253.	1.5	14
218	Understanding Conflicting Neuropathological Findings in Patients Clinically Diagnosed as Having Alzheimer Dementia. JAMA Neurology, 2015, 72, 1106.	4.5	13
219	The presubiculum links incipient amyloid and tau pathology to memory function in older persons. Neurology, 2020, 94, e1916-e1928.	1.5	13
220	Pro: Can biomarkers be gold standards in Alzheimer's disease?. Alzheimer's Research and Therapy, 2010, 2, 17.	3.0	12
221	Anticholinergic Amnesia is Mediated by Alterations in Human Network Connectivity Architecture. Cerebral Cortex, 2019, 29, 3445-3456.	1.6	12
222	IC-P-063: Polygenic Risk of Alzheimerâ€™s Disease is Associated with Early and Late Life Processes. , 2016, 12, P50-P51.		11
223	Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring. Neurobiology of Aging, 2016, 40, 61-67.	1.5	11
224	The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 121-129.	1.2	11
225	Dementia is not synonymous with Alzheimerâ€™s disease. Science Translational Medicine, 2019, 11, .	5.8	11
226	Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trialâ€Ready Cohort study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12135.	1.8	11
227	Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 169-180.	0.4	11
228	KLâˆ—VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOEâˆ—4 carriers. Neurobiology of Aging, 2021, 101, 123-129.	1.5	10
229	Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI. Neurology, 2022, 98, .	1.5	10
230	A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 65, 107-115.	1.2	9
231	Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments. Alzheimer's Research and Therapy, 2019, 11, 4.	3.0	9
232	The neurophysiology and seizure outcomes of late onset unexplained epilepsy. Clinical Neurophysiology, 2020, 131, 2667-2672.	0.7	9
233	Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimerâ€™s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies. SLEEP Advances, 2021, 2, zpab015.	0.1	9
234	To Sleep, Perchance to Delay Dementia. Archives of Neurology, 2012, 69, 118.	4.9	8

#	Article	IF	Citations
235	Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals. NeuroImage: Clinical, 2018, 17, 388-396.	1.4	8
236	Multiple markers contribute to risk of progression from normal to mild cognitive impairment. NeuroImage: Clinical, 2020, 28, 102400.	1.4	8
237	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in nonâ€demented individuals with autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 813-821.	0.4	8
238	Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly. journal of prevention of Alzheimer's disease, The, 2017, 4, 81-86.	1.5	8
239	Development and Validation of a Deep Learning Model for Earlier Detection of Cognitive Decline From Clinical Notes in Electronic Health Records. JAMA Network Open, 2021, 4, e2135174.	2.8	8
240	Association of Î²-Amyloid and Vascular Risk on Longitudinal Patterns of Brain Atrophy. Neurology, 2022, 99, .	1.5	8
241	Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults. NeuroImage: Clinical, 2019, 24, 102097.	1.4	7
242	Functional and Pathological Correlates of Judgments of Learning in Cognitively Unimpaired Older Adults. Cerebral Cortex, 2020, 30, 1974-1983.	1.6	7
243	Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 330-332.	0.9	7
244	The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 104.	3.0	7
245	Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. Neurology, 2020, 95, e1312-e1321.	1.5	7
246	Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimerâ€™s Disease Biomarkers and Mood Symptoms. Frontiers in Aging Neuroscience, 2021, 13, 806432.	1.7	7
247	Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults. Neurology, 2022, 98, .	1.5	7
248	An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. Journal of Alzheimer's Disease, 2019, 68, 1161-1170.	1.2	5
249	THE A4 TRIAL: ANTI-AMYLOID TREATMENT OF ASYMPTOMATIC ALZHEIMER'S DISEASE. , 2014, 10, P246-P246.		3
250	O1â€02â€02: THE ANTIâ€AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMER'S DISEASE (A4) STUDY: REPORT OF SCREENING DATA RESULTS. Alzheimer's and Dementia, 2018, 14, P215.	0.4	3
251	IC-P-162: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P109-P109.		2
252	F4â€03â€03: Antiâ€Amyloid Treatment of Asymptomatic Ad: A4 and Beyond. Alzheimer's and Dementia, 2016, 12, P326.	0.4	2

#	Article	IF	Citations
253	[ICâ€Pâ€181]: LONGITUDINAL TAU ACCUMULATION IS ASSOCIATED WITH COGNITIVE DECLINE IN NORMAL ELDERLY. Alzheimer's and Dementia, 2017, 13, P134.	0.4	2
254	Hypoconnectivity between locus coeruleus and medial temporal lobe during novelty predicts accelerated AÎ²â€•related cognitive decline. Alzheimer's and Dementia, 2020, 16, e041323.	0.4	2
255	Harmonizing the preclinical Alzheimer cognitive composite for multiâ€cohort studies. Alzheimer's and Dementia, 2020, 16, e047423.	0.4	2
256	Amyloidâ€Î² and tau pathologies relate to distinctive brain dysconnectomics in autosomalâ€dominant Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	2
257	O2â€06â€01: Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study. Alzheimer's and Dementia, 2012, 8, P244.	0.4	1
258	P1-180: A NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING INSTRUMENT FOR EARLY ALZHEIMER'S DISEASE. , 2014, 10, P365-P365.		1
259	IC-P-087: DETECTING COGNITIVE PROFILES IN THE BIOMARKER STAGES OF PRECLINICAL AD. , 2014, 10, P49-P50.		1
260	IC-P-117: AMYLOID-B DEPOSITION IN MILD COGNITIVE IMPAIRMENT IS ASSOCIATED WITH HIPPOCAMPAL HYPERACTIVATION, ATROPHY, AND CLINICAL PROGRESSION. , 2014, 10, P65-P66.		1
261	F4-01-04: TAU PET USING F18-T807: INITIAL EXPERIENCE IN NORMAL ELDERLY AND AD DEMENTIA. , 2014, 10, P242-P242.		1
262	P2-246: GREATER SUBJECTIVE COGNITIVE CONCERNS CORRESPOND WITH ADVANCING STAGES OF PRECLINICAL AD. , 2014, 10, P566-P566.		1
263	P4-269: Relationships between baseline biomarkers and subsequent cognitive decline in cognitively unimpaired PSEN1 E280A mutation carriers from the colombian kindred with autosomal dominant Alzheimer's disease. , 2015, 11, P888-P888.		1
264	P1-319: Alzheimer's prevention registry: A shared resource to the scientific community to facilitate enrollment inÂstudies. , 2015, 11, P479-P479.		1
265	O4-01-01: Regional Tau PET measures associated with memory performance in clinically normal older individuals. , 2015, 11, P265-P265.		1
266	F3-03-03: Disclosure of amyloid status in the a4 trial. , 2015, 11, P215-P215.		1
267	IC-P-068: The relationship of cognition, cognitive reserve, and in vivo tau and amyloid burden. , 2015, 11, P51-P51.		1
268	O4-01-04: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P267-P267.		1
269	F5â€04â€03: TRCâ€PAD: Using Runâ€in Data for Screen Failure Reduction. Alzheimer's and Dementia, 2016, 12, P372.	0.4	1
270	F5-05-02: The Harvard Automated Phone Task (APT): A Novel Performance-Based ADL Instrument for Early Alzheimerâ€™s Disease. , 2016, 12, P373-P373.		1

#	Article	IF	Citations
271	ICâ€Pâ€013: Pet Staging of Amyloidosis: Evidence that Amyloid Occurs First in Neocortex and Later in Striatum. Alzheimer's and Dementia, 2016, 12, P20.	0.4	1
272	IC-P-043: Neuroimaging Correlates of Anosognosia in Mild Cognitive Impairment. , 2016, 12, P36-P37.		1
273	O2â€03â€02: are White Matter Hyperintensities a Core Feature of Alzheimerâ€™s Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2016, 12, P226.	0.4	1
274	O4â€06â€06: The Impact of Anosognosia and Anosodiaphoria on the Prediction of Progression from Mild Cognitive Impairment to Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P346.	0.4	1
275	P4-354: Subjective Cognitive Concerns are Associated with Objective Memory Performance in Older Caucasian but not African-American Persons. , 2016, 12, P1173-P1173.		1
276	[P3â€“376]: QRISK2 AND FRAMINGHAM CARDIOVASCULAR RISK SCORES SIGNIFICANTLY CORRELATE WITH IMAGING BIOMARKERS OF PRECLINICAL AD: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P1103.	0.4	1
277	[ICâ€02â€“03]: TAU AND HIPPOCAMPAL VOLUME REFLECT DISTINCT PROCESSES IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P5.	0.4	1
278	[O1â€“02â€“05]: GENOTYPIC VARIANCE MAY EXPLAIN THE BALANCE OF EARLY CORTICAL VERSUS STRIATAL AMYLOID DEPOSITION IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P187.	0.4	1
279	[P4â€“500]: SPATIAL PATTERNS OF FLORTAUCIPIR (FTP) SIGNAL IN COGNITIVELY NORMAL ELDERLY. Alzheimer's and Dementia, 2017, 13, P1530.	0.4	1
280	[P4â€“534]: LINKING MEASURES OF SUBJECTIVE COGNITION ACROSS INTERNATIONAL AGING STUDIES USING ITEM RESPONSE THEORY. Alzheimer's and Dementia, 2017, 13, P1554.	0.4	1
281	ICâ€Pâ€041: LONGITUDINAL CHANGE OF FUNCTIONAL CONNECTIVITY IN PRECLINICAL AD: RESULTS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2018, 14, P41.	0.4	1
282	O1â€08â€03: DIGITIZED CLOCK DRAWING (DCTCLOCK^{TM}) PERFORMANCE AND ITS RELATIONSHIP TO AMYLOID AND TAU PET IMAGING MARKERS IN UNIMPAIRED OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P236.	0.4	1
283	P4â€094: OCCIPITAL TO GLOBAL PIB UPTAKE IS ASSOCIATED WITH THE PRESENCE OF MICROHEMORRHAGES AND MUTATIONS ASSOCIATED WITH CEREBRAL AMYLOID ANGIOPATHY IN THE DOMINANTLY INHERITED ALZHEIMER'S NETWORK. Alzheimer's and Dementia, 2018, 14, P1472.	0.4	1
284	P1â€480: LOCUS COERULEUS SIGNAL INTENSITY IS ASSOCIATED WITH ENTORHINAL TAU PATHOLOGY AT HIGHER LEVELS OF AMYLOID BURDEN. Alzheimer's and Dementia, 2018, 14, P509.	0.4	1
285	ICâ€02â€04: REGIONAL ASYMMETRIES IN AMYLOID AND TAU GO TOGETHER: EVIDENCE FOR LOCAL INTERACTION. Alzheimer's and Dementia, 2018, 14, P4.	0.4	1
286	ICâ€Pâ€147: QUANTIFYING STAGES OF SUBTLE MEMORY IMPAIRMENT IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P125.	0.4	1
287	Repeated memoryâ€based assessments: Implications for clinical trials and practice. Alzheimer's and Dementia, 2020, 16, e038143.	0.4	1
288	Trajectories of decline in cognitively complex everyday activities across the Alzheimerâ€™s disease continuum. Alzheimer's and Dementia, 2020, 16, e044787.	0.4	1

#	Article	IF	Citations
289	Initial exploration of a brain age score based on validated computerized cognitive assessments in Japanese individuals. Alzheimer's and Dementia, 2020, 16, e045446.	0.4	1
290	Longitudinal hippocampal atrophy is associated with an amyloidâ€independent entorhinal tauopathy and an amyloidâ€dependent neocortical tauopathy. Alzheimer's and Dementia, 2020, 16, e045733.	0.4	1
291	Dementia knowledge and associated demographic factors within a registry sample. Alzheimer's and Dementia, 2020, 16, e046177.	0.4	1
292	Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimerâ€™s disease. Neurotherapeutics, 2005, 2, 348-360.	2.1	1
293	AHEAD 3â€45 study: Preliminary screening and baseline characteristics from a placeboâ€controlled, doubleâ€blind study evaluating lecanemab in participants with preclinical Alzheimerâ€™s disease and elevated (A45 trial) and intermediate (A3 trial) amyloid. Alzheimer's and Dementia, 2021, 17, .	0.4	1
294	CSF polygenic risk AD biomarkers predict brain amyloid and free recall. Alzheimer's and Dementia, 2021, 17, .	0.4	1
295	Extraneous neuroimaging factors do not contribute to sex differences in flortaucipir signal: Analysis of skull binding and partial volume effects. Alzheimer's and Dementia, 2021, 17, .	0.4	1
296	Associations between remote cognitive testing on an individualâ€™s own digital device and amyloid burden on neuroimaging in clinically normal older adults: Results from Boston Remote Assessment for Neurocognitive Health (BRANCH). Alzheimer's and Dementia, 2021, 17, .	0.4	1
297	Reduced amyloid and greater neuropsychological testing exclusion in the A4 study in individuals that selfâ€identify as nonâ€Hispanic Asian. Alzheimer's and Dementia, 2021, 17, .	0.4	1
298	The impact of COVIDâ€19 on the wellâ€being and cognition of older adults living in the United States and Latin America. Alzheimer's and Dementia, 2021, 17, .	0.4	1
299	Menopause moderates sex differences in tau PET signal: Findings from the Framingham Study. Alzheimer's and Dementia, 2021, 17, .	0.4	1
300	O1-07-01: Alzheimer's-signature MRI biomarker predicts likelihood of Alzheimer's dementia in cognitively normal adults. , 2011, 7, S109-S109.		0
301	O2-01-01: Plasma and Cerebrospinal Fluid Markers in the DIAN Study of Autosomal-Dominant Alzheimer's Disease. , 2011, 7, S287-S287.		0
302	F5-03-03: Discussant. , 2013, 9, P826-P826.		0
303	O4-06-03: Genotype-phenotype studies examining the CD33 locus and amyloid biology. , 2013, 9, P692-P693.		0
304	IC-O1-02: Are early atrophy patterns in autosomal dominant familial Alzheimer's disease gene-dependent?. , 2013, 9, P3-P4.		0
305	P3-266: NEUROPSYCHIATRIC SYMPTOMS AND FUNCTIONAL CONNECTIVITY IN MILD COGNITIVE IMPAIRMENT AND COGNITIVELY NORMAL ELDERLY. , 2014, 10, P729-P729.		0
306	O3-07-02: WHITE MATTER BURDEN IN CLINICALLY NORMAL OLDER ADULTS MEDIATES THE RELATIONSHIP BETWEEN AMYLOID BURDEN AND MEMORY FREE RECALL BUT NOT CUED RECALL. , 2014, 10, P221-P222.		0

#	Article	IF	Citations
307	P4-069: DEVELOPMENT OF A PROCESS TO DISCLOSE AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL OLDER ADULT RESEARCH PARTICIPANTS. , 2014, 10, P808-P808.		0
308	DT-01-02: TEMPORAL NEOCORTICAL TAU DEPOSITION MEASURED WITH PET IS ASSOCIATED WITH LONGITUDINAL DECLINE IN MEMORY PERFORMANCE AMONG CLINICALLY NORMAL ELDERLY. , 2014, 10, P280-P280.		0
309	P2-154: SUBSYNDROMAL DEPRESSION AND ALZHEIMER'S DISEASE BIOMARKERS IN COGNITIVELY NORMAL ELDERLY. , 2014, 10, P527-P528.		0
310	IC-P-152: OLFACTORY IDENTIFICATION AND ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY NORMAL ELDERLY. , 2014, 10, P87-P87.		0
311	O3-10-06: AMYLOID-Î² DEPOSITION IN MILD COGNITIVE IMPAIRMENT IS ASSOCIATED WITH HIPPOCAMPAL HYPERACTIVATION, ATROPHY, AND CLINICAL PROGRESSION. , 2014, 10, P230-P230.		0
312	P1-301: OLFACTORY IDENTIFICATION AND ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY NORMAL ELDERLY. , 2014, 10, P422-P422.		0
313	IC-02-01: GREATER SUBJECTIVE COGNITIVE CONCERNS CORRESPOND WITH ADVANCING STAGES OF PRECLINICAL AD. , 2014, 10, P4-P4.		0
314	O4-12-04: DETECTING COGNITIVE PROFILES IN THE BIOMARKER STAGES OF PRECLINICAL AD. , 2014, 10, P276-P276.		0
315	P4-140: AMYLOID BURDEN-RELATED PERFORMANCE DIFFERENCES ON COGNITIVE AND FUNCTIONAL INSTRUMENTS ACROSS ALZHEIMER'S DISEASE PATHOPHYSIOLOGIC STAGES. , 2014, 10, P839-P839.		0
316	IC-P-084: Neurobiological correlates of anosognosia in mild cognitive impairment: A multimodal investigation using FDG-PET, PiB-PET, and volumetric MRI. , 2015, 11, P60-P60.		0
317	IC-P-125: Location, location, location: The distributed effects of amyloid on functional connectivity in the harvard aging brain study. , 2015, 11, P85-P86.		0
318	P4-083: Hippocampal metabolism is decreased in high-amyloid mild cognitive impairment but not in high-amyloid clinically normal elders. , 2015, 11, P802-P803.		0
319	P3-217: Moderate caffeine consumption is associated with better memory scores in clinically normal older adults. , 2015, 11, P715-P716.		0
320	IC-P-071: Instrumental activities of daily living and functional connectivity in mild cognitive impairment. , 2015, 11, P53-P53.		0
321	IC-P-085: Regional Tau PET measures associated with memory performance in clinically normal older individuals. , 2015, 11, P60-P61.		0
322	IC-P-156: Baseline amyloid PET imaging, longitudinal amyloid accumulation, and Tau PET imaging in preclinical Alzheimer's disease. , 2015, 11, P105-P105.		0
323	P3-162: Instrumental activities of daily living and functional connectivity in mild cognitive impairment. , 2015, 11, P690-P691.		0
324	O4-01-03: Entorhinal tau deposition is associated with parietal association cortex hypometabolism in clinically normal older individuals. , 2015, 11, P266-P267.		0

#	Article	IF	Citations
325	P3-104: Associations between subjective memory complaints and hippocampal volume in preclinical early-onset Alzheimer's disease. , 2015, 11, P660-P661.		0
326	F3-02-02: Snap in cognitively normal adults. , 2015, 11, P213-P213.		0
327	P2-141: Neurobiological correlates of anosognosia in mild cognitive impairment: A multi-modal investigation using FDG-PET, PiB-PET, and volumetric MRI. , 2015, 11, P540-P540.		0
328	O3-09-06: Location, location, location: The distributed effects of amyloid on functional connectivity in the harvard aging brain study. , 2015, 11, P240-P240.		0
329	O5-01-01: Tau and amyloid deposits relate to distinctive cortical atrophy patterns in cognitively normal elderly. , 2015, 11, P311-P312.		0
330	P3-135: Clinical and neuroimaging predictors of psychological well-being as measured by the purpose in life scale in cognitively normal older individuals. , 2015, 11, P675-P676.		0
331	IC-P-153: Clinical and neuroimaging predictors of psychological well-being as measured by the purpose in life scale in cognitively normal older individuals. , 2015, 11, P102-P103.		0
332	O1-06-05: Baseline amyloid PET imaging, longitudinal amyloid accumulation, and Tau PET imaging in preclinical Alzheimer's disease. , 2015, 11, P139-P139.		0
333	O2-02-03: The relationship of cognition, cognitive reserve, and in vivo tau and amyloid burden. , 2015, 11, P175-P175.		0
334	O2-02-05: Differential declines in letter versus category fluency over 4 years in biomarker-defined preclinical Alzheimer's disease. , 2015, 11, P176-P177.		0
335	O2-11-06: Reciprocal relations of loneliness and cognitive function in older u.s. adults. , 2015, 11, P201-P202.		0
336	P3â€309: Profiles of Cognitive Decline Associated with Biomarkerâ€Defined Preclinical Stages of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P960.	0.4	0
337	P3-275: Increased TAU PET Signal Associated with Longitudinal Mr Atrophy in Cognitively Normal Older Adults. , 2016, 12, P940-P941.		0
338	P4-217: Regional Fluorodeoxyglucose Hypometabolism is Associated With Greater Apathy Over Time in Early Alzheimer's Disease. , 2016, 12, P1111-P1111.		0
339	P4-396: Using an Internet Registry to Supplement Recruitment Efforts for Clinical Research. , 2016, 12, P1189-P1189.		0
340	ICâ€Pâ€053: Regional Fluorodeoxyglucose Hypometabolism is Associated with Greater Apathy Over Time in Early Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P43.	0.4	0
341	P2-341: Subjective Cognitive Decline Predicts Longitudinal Decline in those with Both Amyloidosis and Neurodegeneration. , 2016, 12, P773-P774.		0
342	P3-322: Optimal Memory Performance in Older Adults is Associated with Differences in Hippocampal Volume and Amyloid Status at Baseline and Over 3 Years. , 2016, 12, P969-P969.		0

#	Article	IF	Citations
343	ICâ€Pâ€185: The Effect of Tractâ€Specific Loss of White Matter Connectivity on Cognitive Decline in Healthy Older Individuals Depends on Entorhinal T807 Binding. Alzheimer's and Dementia, 2016, 12, P135.	0.4	0
344	ICâ€Pâ€190: Increased TAU PET Signal Associated with Longitudinal Mr Atrophy in Cognitively Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P137.	0.4	0
345	F1â€04â€01: Longitudinal Peformance on the Preclinical Alzheimerâ€™s Cognitive Composite (PACC) in Subjects with Biomarkerâ€Defined Preclincal ad. Alzheimer's and Dementia, 2016, 12, P167.	0.4	0
346	O1â€13â€01: Anxiety, Social Activity and Amyloid in Cognitively Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P208.	0.4	0
347	F3-04-01: In Vivo Cortical Distribution of Tau and Amyloid Deposits in Cognitively Normal Elderly. , 2016, 12, P274-P274.		0
348	O3â€08â€03: The Effect of Tractâ€Specific Loss of White Matter Connectivity on Cognitive Decline in Healthy Older Individuals Depends on Entorhinal T807 Binding. Alzheimer's and Dementia, 2016, 12, P304.	0.4	0
349	O3â€09â€03: Associations between Amyloidosis and Longitudinal Cognitive Decline in Clinically Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P308.	0.4	0
350	O4â€01â€02: Tau and Amyloid Pet Imaging in a Colombian Kindred with Autosomalâ€Dominant Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P330.	0.4	0
351	O4â€01â€06: Ab+ Clinically Normal Participants with Elevated Tau Show Greatest Decline in the Preclinical Alzheimerâ€™s Disease Cognitive Composite. Alzheimer's and Dementia, 2016, 12, P333.	0.4	0
352	O4-06-04: Neuroimaging Correlates of Anosognosia in Mild Cognitive Impairment. , 2016, 12, P345-P346.		0
353	O4â€07â€05: Pet Staging of Amyloidosis: Evidence that Amyloid Occurs First in Neocortex and Later in Striatum. Alzheimer's and Dementia, 2016, 12, P349.	0.4	0
354	P4-325: TAU BURDEN is Associated with Subjective Cognitive Concerns in the Context of Î²-Amyloid Burden in Preclinical ad. , 2016, 12, P1158-P1159.		0
355	FTS2-01-05: From the who Research Priorities and Research Portfolio Analysis to the Identification of Research Gaps to Reduce the Global Burden of Dementia. , 2016, 12, P220-P220.		0
356	F4-03-01: Collaboration for Alzheimer's Prevention (CAP): Advancing the Evaluation of Preclinical Alzheimer's Disease Treatments. , 2016, 12, P325-P326.		0
357	ICâ€Pâ€198: TAU and Amyloid PET Imaging in a Colombian Kindred with Autosomalâ€Dominant Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P143.	0.4	0
358	[O4â€“07â€“06]: IN VIVO SPREADING PATHWAYS OF TAU AND AMYLOID ACCUMULATION AND ITS GENETIC UNDERPINNINGS. Alzheimer's and Dementia, 2017, 13, P1246.	0.4	0
359	[P4â€“228]: LONGITUDINAL TAU ACCUMULATION IS ASSOCIATED WITH COGNITIVE DECLINE IN NORMAL ELDERLY. Alzheimer's and Dementia, 2017, 13, P1357.	0.4	0
360	[P4â€“243]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P1369.	0.4	0

#	Article	IF	Citations
361	[P1â€“154]: APOE Îµ4 IS ASSOCIATED WITH HIGHER TDPâ€43 PROTEINOPATHY BURDEN IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P301.	0.4	0
362	[ICâ€Pâ€041]: SAMPLE SIZES FOR 24â€MONTH ALZHEIMER's PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOIDâ€POSITIVE ADULTS. Alzheimer's and Dementia, 2017, 13, P36.	0.4	0
363	[ICâ€Pâ€089]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P72.	0.4	0
364	[ICâ€Pâ€108]: ASSOCIATIONS BETWEEN MEASURES OF MEDIAL TEMPORAL LOBE NEURODEGENERATION AND ANOSOGNOSIA FOR MEMORY DEFICITS. Alzheimer's and Dementia, 2017, 13, P85.	0.4	0
365	[P1â€“256]: BASELINE CARDIOVASCULAR RISK AND AMYLOID BURDEN SYNERGISTICALLY PREDICT LONGITUDINAL COGNITIVE DECLINE IN CLINICALLY NORMAL ELDERLY: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P347.	0.4	0
366	[P1â€“398]: TAU ACCUMULATION IS DETECTABLE AND CORRELATED TO AMYLOID BURDEN IN NORMAL AND IMPAIRED OLDER INDIVIDUALS USING SERIAL PET. Alzheimer's and Dementia, 2017, 13, P423.	0.4	0
367	[P1â€“434]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVITY IN THE DEFAULT MODE NETWORK IN AUTOSOMALâ€DOMINANT ALZHEIMER's DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P448.	0.4	0
368	[P2â€“115]: A TMEM106B LOCUS IS IMPLICATED IN COGNITIVE DECLINE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P650.	0.4	0
369	[P2â€“298]: ASSOCIATIONS BETWEEN MEASURES OF MEDIAL TEMPORAL LOBE NEURODEGENERATION AND ANOSOGNOSIA FOR MEMORY DEFICITS. Alzheimer's and Dementia, 2017, 13, P730.	0.4	0
370	[F1â€“03â€“02]: SUBJECTIVE COGNITIVE DECLINE, LONGITUDINAL COGNITIVE PERFORMANCE, AND IMAGING BIOMARKERS IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P176.	0.4	0
371	[O1â€“13â€“01]: SUBJECTIVE CONCERNS PREFERENTIALLY ASSOCIATE WITH AMYLOID BURDEN AND MEMORY IN CAUCASIANS, BUT WHITE MATTER HYPERINTENSITIES AND EXECUTIVE FUNCTION IN AFRICANâ€AMERICANS. Alzheimer's and Dementia, 2017, 13, P225.	0.4	0
372	[O2â€“10â€“03]: SEVERITY OF SUBJECTIVE COGNITIVE DECLINE ALIGNS WITH REGIONAL AMYLOID SEVERITY: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P577.	0.4	0
373	[O2â€“11â€“04]: COGNITIVE RESERVE RELATES TO GREATER FUNCTIONAL CONNECTIVITY AND STRONGER INTERCONNECTIVITY WITHIN AND BETWEEN NODES, INDEPENDENT OF Î²â€AMYLOID: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P582.	0.4	0
374	[F3â€“05â€“03]: OBJECTIVE AND SUBJECTIVE COGNITIVE DECLINE IN BLACK AMERICANS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2017, 13, P885.	0.4	0
375	[O3â€“06â€“02]: SEMANTIC MEMORY AND PET AMYLOID AND TAU DEPOSITION IN PRECLINICAL AND PRODROMAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P911.	0.4	0
376	[O3â€“07â€“06]: THE RELATIONSHIP BETWEEN RECALL OF RECENTLY VERSUS REMOTELY ENCODED FAMOUS FACES AND AMYLOID AND TAU BURDEN IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P917.	0.4	0
377	[P1â€“030]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVITY IN THE DEFAULT MODE NETWORK IN AUTOSOMALâ€DOMINANT ALZHEIMER's DISEASE: A PRELIMINARY REPORT. Alzheimer's and Dementia, 2017, 13, P245.	0.4	0
378	O4â€09â€01: COMPARISON OF THE NATURAL HISTORY OF NEOCORTICAL AÎ²â€AMYLOID, HIPPOCAMPAL VOLUME AND PACC IN SPORADIC AD. Alzheimer's and Dementia, 2018, 14, P1423.	0.4	0

#	Article	IF	Citations
379	O3â€12â€01: DECREASED METAâ€MEMORY FOR EPISODIC BUT NOT SEMANTIC INFORMATION IS ASSOCIATED WITH EARLY TAUOPATHY IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1050.	0.4	0
380	P1â€327: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNITIVE DECLINE IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P417.	0.4	0
381	P3â€136: MODULE QUANTITATIVE TRAIT LOCI ANALYSIS IMPLICATES TMEM106B AND RBFOX1 AS KEY BRAIN TRANSCRIPTOME REGULATORS IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1120.	0.4	0
382	P3â€370: AN APOEÎµ4 DERIVED STATISTICAL METHOD FOR OPTIMIZING TARGET AND REFERENCE REGIONS FOR AMYLOIDâ€PET IMAGING. Alzheimer's and Dementia, 2018, 14, P1231.	0.4	0
383	P3â€290: AMYLOID PATHOLOGY EXPLAINS UNAWARENESS OF MEMORY DEFICITS ABOVE AND BEYOND CORTICAL THICKNESS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P1191.	0.4	0
384	O3â€04â€03: AMYLOID IS ASSOCIATED WITH GREATER TAU BURDEN IN CLINICALLY NORMAL FEMALES RELATIVE TO MALES: FINDINGS FROM TWO INDEPENDENT COHORTS. Alzheimer's and Dementia, 2018, 14, P1019.	0.4	0
385	O1â€02â€01: IMPACT OF DISCLOSING AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL RESEARCH PARTICIPANTS: THE A4 EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P215.	0.4	0
386	ICâ€Pâ€159: BRAIN RESILIENCE PROTECTS AGAINST COGNITIVE DECLINE ASSOCIATED WITH ELEVATED AMYLOID BURDEN. Alzheimer's and Dementia, 2018, 14, P134.	0.4	0
387	F4â€08â€02: AMYLOID BURDEN AND VASCULAR RISK ARE INDEPENDENTLY ASSOCIATED WITH SUBJECTIVE COGNITIVE DECLINE IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1394.	0.4	0
388	P2â€452: TAU ACCUMULATION IN RHINAL CORTEX IS ASSOCIATED WITH MEMORY PERFORMANCE IN NONDEMENTED YOUNG ADULTS WITH AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P892.	0.4	0
389	O1â€02â€05: PREDICTING AMYLOID BURDEN IN SCREENING FOR PRECLINICAL AD PREVENTION TRIALS. Alzheimer's and Dementia, 2018, 14, P217.	0.4	0
390	O1â€10â€03: SEX AND APOE GENOTYPE INFLUENCE THE ASSOCIATION BETWEEN AMYLOID AND LONGITUDINAL TAU PATHOLOGY IN CLINICALLY NORMAL OLDER ADULTS: FINDINGS FROM THE ADNI STUDY. Alzheimer's and Dementia, 2018, 14, P243.	0.4	0
391	ICâ€Pâ€215: TAU ACCUMULATION IN RHINAL CORTEX IS ASSOCIATED WITH MEMORY PERFORMANCE IN NONâ€DEMENTED YOUNG ADULTS WITH AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P176.	0.4	0
392	ICâ€Pâ€139: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNITIVE DECLINE IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P116.	0.4	0
393	P4â€118: AV1451 TAU PET, BUT NOT CSF TAU, IS RELATED TO MEMORY DECLINE IN PRECLINICAL AND PRODROMAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1484.	0.4	0
394	P1â€301: CERTAIN PLASMA Nâ€TERMINAL TAU FRAGMENTS ARE ELEVATED IN AD AND ADâ€MCI COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P405.	0.4	0
395	ICâ€Pâ€140: TAU ACCUMULATION AND MEMORY DECLINE ARE MORE CLOSELY RELATED TO STRIATAL THAN CORTICAL AMYLOIDOSIS IN INDIVIDUALS WITH EARLYâ€ONSET AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P117.	0.4	0
396	P2â€461: ENTORHINAL TAU PATHOLOGY IS ASSOCIATED WITH WHITE MATTER ABNORMALITIES IN UNCINATE FASCICULUS IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P897.	0.4	0

#	Article	IF	Citations
397	O2â€08â€06: AMYLOIDâ€Î², COGNITION AND SOCIAL ACTIVITY IN COGNITIVELY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P640.	0.4	0
398	0300 Linking Sleep Disturbances with Amyloid and Tau Imaging. Preliminary Findings from the Harvard Aging Brain Study. Sleep, 2019, 42, A122-A123.	0.6	0
399	P4â€496: MYELOID CELLâ€SPECIFIC ALZHEIMER'S DISEASE POLYGENIC RISK SCORE PREDICTS NEURODEGENERATION AND Aî²â€RELATED COGNITIVE DECLINE IN COGNITIVELY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2019, 15, P1503.	0.4	0
400	ICâ€Pâ€178: SEX DIFFERENCES IN TAU PATHOLOGY ACROSS CORTICAL AND SUBCORTICAL REGIONS OF INTEREST: FINDINGS ACROSS TWO COHORTS. Alzheimer's and Dementia, 2019, 15, P139.	0.4	0
401	P4â€607: FREE AND CUED MEMORY IS DISTINCTLY RELATED TO PATHOLOGY IN PRECLINICAL AUTOSOMALâ€DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1557.	0.4	0
402	ICâ€Pâ€037: GERIATRIC DEPRESSION SCALE ITEMâ€LEVEL ANALYSIS IN RELATION TOÂIN VIVO CORTICAL AMYLOID AND CEREBRAL REGIONAL TAU IN CLINICALLY NORMAL OLDER ADULTS: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2019, 15, P43.	0.4	0
403	ICâ€Pâ€089: ASSOCIATIONS OF REGIONAL CORTICAL THINNING AND LONGITUDINAL COGNITIVE PERFORMANCE IN THE CONTEXT OF AMYLOID IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2019, 15, P79.	0.4	0
404	F2â€03â€01: CLINICAL MEANINGFULNESS OF SHORTâ€TERM COGNITIVE DECLINE ON THE PRECLINICAL ALZHEIMER'S COGNITIVE COMPOSITEâ€5 (PACCâ€5) IN NORMAL OLDER ADULTS WITH ELEVATED Î²â€AMYLOID. Alzheimer's and Dementia, 2019, 15, P518.	0.4	0
405	ICâ€Pâ€008: ANATOMICAL STAGING OF BETAâ€AMYLOID ACCUMULATION BASED ON LONGITUDINAL ASSESSMENT OF GLOBALLY PIB NEGATIVE ADULTS. Alzheimer's and Dementia, 2019, 15, P18.	0.4	0
406	P4â€608: TAU ACCUMULATION AND VISUAL MEMORY IN COGNITIVELY UNIMPAIRED PSEN1 E280A MUTATION CARRIERS. Alzheimer's and Dementia, 2019, 15, P1557.	0.4	0
407	ICâ€Pâ€058: COVARYING SPATIAL PATTERNS OF TAU DEPOSITION AND GRAY MATTER ATROPHY UNEARTHED BY THE INFORMED MULTIMODAL PARTIAL LEAST SQUARES (MMPLS) IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: FINDINGS FROM THE COLBOS PROJECT. Alzheimer's and Dementia, 2019, 15, P58.	0.4	0
408	O3â€09â€01: PROTECTIVE EFFECT OF PHYSICAL ACTIVITY ON LONGITUDINAL COGNITIVE DECLINE AND NEURODEGENERATION IN CLINICALLY NORMAL OLDER ADULTS WITH ELEVATED Î²â€AMYLOID BURDEN. Alzheimer's and Dementia, 2019, 15, P903.	0.4	0
409	Tracking the origin of tau spread in the brain. Alzheimer's and Dementia, 2020, 16, e037501.	0.4	0
410	Association of tau tangle burden with depressive symptoms in communityâ€dwelling older adults: A longitudinal study. Alzheimer's and Dementia, 2020, 16, e038867.	0.4	0
411	Sex, tau, and cortical thinning in the temporal lobe: Findings from the Harvard Aging Brain Study. Alzheimer's and Dementia, 2020, 16, e040031.	0.4	0
412	The dynamic interplay between longitudinal subjective and objective cognitive decline along the early AD spectrum in the Harvard Aging Brain Study. Alzheimer's and Dementia, 2020, 16, e040260.	0.4	0
413	Evaluating preâ€screening tools for older Latino recruitment into preclinical Alzheimerâ€™s disease studies. Alzheimer's and Dementia, 2020, 16, e041571.	0.4	0
414	The relationship between cortical microstructural changes and in vivo amyloidâ€Î² and tau in aging and preclinical Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e041626.	0.4	0

#	Article	IF	Citations
415	Genetic associations with brain amyloidosis. Alzheimer's and Dementia, 2020, 16, e042191.	0.4	0
416	The antiâ€amyloid treatment in asymptomatic Alzheimerâ€™s disease (A4) study: Report of screening and recruitment characteristics of the Melbourne composite site. Alzheimer's and Dementia, 2020, 16, e042786.	0.4	0
417	Sex differences in genetic predictors of resilience to Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043259.	0.4	0
418	Longitudinal inferior temporal FTPâ€PET signal increase is associated with contemporaneous longitudinal temporal lobe cortical thinning in preclinical Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043419.	0.4	0
419	Estimating an individual's placement on a theoretical continuum using longitudinal cognitive trajectories: Relationships with longitudinal amyloid and Tauâ€PET. Alzheimer's and Dementia, 2020, 16, e043566.	0.4	0
420	Faster rates of tau accumulation in FTPâ€PET in females relative to males, and a crossâ€sectional influence on faster cognitive decline: Preliminary findings from HABS and ADNI. Alzheimer's and Dementia, 2020, 16, e043620.	0.4	0
421	Associations of peak width of skeletonized mean diffusivity with cardiovascular disease risk and cognitive decline in clinically normal older adults. Alzheimer's and Dementia, 2020, 16, e043812.	0.4	0
422	Vascular risk and physical activity as modulators of cognitive and neurodegenerative trajectories: Independent and interactive effects with betaâ€amyloid. Alzheimer's and Dementia, 2020, 16, e044145.	0.4	0
423	Are amyloid and tau synergistic? How to interpret an amyloid/tau interaction on cognitive decline in clinically normal adults. Alzheimer's and Dementia, 2020, 16, e044310.	0.4	0
424	Study partner factors on cognitive function index scores among participants screened for the A4 study. Alzheimer's and Dementia, 2020, 16, e044871.	0.4	0
425	Alternatives to MMRM for preclinical Alzheimerâ€™s clinical trials. Alzheimer's and Dementia, 2020, 16, e044915.	0.4	0
426	Plasma levels of an Nâ€terminal tau fragment are highly associated with future cognitive decline and neurodegeneration in clinically normal elderly. Alzheimer's and Dementia, 2020, 16, e045261.	0.4	0
427	Plasma ILâ€12/IFNâ€Î³ axis predicts cognitive trajectories in cognitively normal older adults. Alzheimer's and Dementia, 2020, 16, e045497.	0.4	0
428	Multimodal genomeâ€wide metaâ€analysis of brain amyloidosis reveals heterogeneity across CSF, PET, and pathological amyloid measures. Alzheimer's and Dementia, 2020, 16, e046009.	0.4	0
429	Distinct contributions of longitudinal tau and amyloid to decline in various cognitive domains in preclinical AD. Alzheimer's and Dementia, 2020, 16, e046075.	0.4	0
430	Surfaceâ€based amyloid and tau correlates of digital clock drawing performance. Alzheimer's and Dementia, 2020, 16, e046461.	0.4	0
431	Depressive symptoms are associated with hippocampal neurodegeneration in preclinical autosomal dominant Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e046495.	0.4	0
432	Association of tau tangle burden with depressive symptoms in communityâ€dwelling older adults: A longitudinal study. Alzheimer's and Dementia, 2020, 16, e046549.	0.4	0

#	Article	IF	Citations
433	Longitudinal increase in depressive symptoms in relation to neurodegeneration in clinically normal older adults: Findings from the Harvard Aging Brain Study. Alzheimer's and Dementia, 2020, 16, e047321.	0.4	0
434	P3â€399: ASSOCIATION BETWEEN CORTICAL THINNING AND TAU PATHOLOGY IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1253.	0.4	0
435	Brainstem volume is negatively associated with amyloid deposition in the Framingham Heart Study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
436	Cortical microstructure is associated with tau burden and predicts cognitive decline and clinical progression in healthy older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
437	Trajectories of selfâ€rated concerns in individuals developing cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	0
438	Associations between biomarker status (amyloid, tau) and risk for progression to MCI/Dementia in the Harvard Aging Brain Study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
439	Locus coeruleus integrity as a proxy of initial tau burden: in vivo versus ex vivo observations. Alzheimer's and Dementia, 2021, 17, .	0.4	0
440	Greater psychological resilience during the COVIDâ€19 pandemic is associated with lower tau burden in cognitively unimpaired individuals. Alzheimer's and Dementia, 2021, 17, .	0.4	0
441	Sequential early cognitive changes sensitive to rising betaâ€amyloid and tau pathology in preclinical AD. Alzheimer's and Dementia, 2021, 17, .	0.4	0
442	Cognition and hippocampal volume in amyloid positive clinically normal adults: Results from the A4 study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
443	Longitudinal associations between amyloid and tauâ€PET: Impact for prevention trials. Alzheimer's and Dementia, 2021, 17, .	0.4	0
444	Associations between plasma pâ€tau217, in vivo brain pathology and cognition in individuals with autosomalâ€dominant Alzheimerâ€™s disease: Findings from the Colombiaâ€Boston (COLBOS) biomarker study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
445	Selfâ€reported history of estrogen hormone therapy differentiates rates of amyloid accumulation (PiBâ€PET) relative to males: Findings from the Harvard Aging Brain Study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
446	Amygdala tau pathology in preclinical autosomal dominant Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
447	The combined influence of betaâ€amyloid and vascular risk on prospective brain atrophy in clinically normal individuals. Alzheimer's and Dementia, 2021, 17, .	0.4	0
448	Longitudinal trajectories of remote assessment of selfâ€and study partnerâ€rated cognitive concerns, mood and Alzheimerâ€™s disease biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	0
449	Monthly computerized atâ€home assessments to detect cognitive change in preclinical Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
450	Regional betaâ€amyloid and tau deposition: Results from the Framingham Heart Study. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	Citations
451	Resilience and perceived stress in cognitively normal older adults during the COVIDâ€19 pandemic. Alzheimer's and Dementia, 2021, 17, .	0.4	0
452	Multimodal neuroimaging biomarkers of Alzheimerâ€™s disease in older adults with depression: Preliminary findings from a pilot cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	0
453	The location of PSEN1 pathogenic variants in transmembrane vs. cytoplasmic domains may alter neurodegenerative and cognitive trajectories: Findings from the DIAN study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
454	Associations Between Brainstem Volume and Alzheimerâ€™s Disease Pathology in Middle-Aged Individuals of the Framingham Heart Study. Journal of Alzheimer's Disease, 2022, 86, 1603-1609.	1.2	0
455	Locus coeruleus integrity predicts tau accumulation and memory dysfunction in autosomal dominant Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e052664.	0.4	0
456	Sex differences in the genetic architecture underlying resilience in AD.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055010.	0.4	0
457	Cell type-specific Alzheimer's disease polygenic risk scores are associated with distinct disease processes in preclinical Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055304.	0.4	0
458	Sex-specific genetic predictors of memory performance.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e056083.	0.4	0